Navigation Links
Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
Date:11/2/2010

ch Equity Act (PREA) requirement included in the new drug application (NDA) approval for OFIRMEV, Cadence will conduct a post-marketing efficacy study of OFIRMEV in infants and neonates. The company expects to commence this study in 2011.  

Conference Call and Webcast Details

Cadence management will host a conference call on Tuesday, November 2, 2010 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time and interested investors may participate in the conference call by dialing (877) 303 – 9145 (domestic) or  (760) 536-5203 (international). To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website for thirty days through December 2, 2010.

About OFIRMEV™ (Acetaminophen) Injection

OFIRMEV (acetaminophen) injection is Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen. OFIRMEV is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.

For more information, please see the complete OFIRMEV Prescribing Information, available at http://www.Ofirmev.com or www.cadencepharm.com.

Important Safety Information:

OFIRMEV should be administered only as a 15 minute intravenous infusion. Do not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of t
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
8. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
9. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
10. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... 2014 Sleep disturbances such as ... correlated with depression. According to a study published ... three quarters of depressed patients have insomnia symptoms, ... young depressed adults and 10% of older patients, ... huge distress, have a major impact on quality ...
(Date:7/18/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... operating officer and president, has resigned, effective July 31, ... consultant going forward on special projects. His resignation is ... this position since September 2013. On an interim basis, ... , who has been Neogen,s chief executive officer since ...
(Date:7/18/2014)... (PRWEB) July 18, 2014 Global ... with US offices in Cambridge, MA, announces the ... Assay and Software product that leverages the power ... the Illumina® MiSeq sequencing platform. The assay and ... Children’s Hospital of Philadelphia (CHOP) and will include ...
(Date:7/18/2014)... 2014 Provia Laboratories announces the addition ... Board. Dr. Vaught has worked in the field ... As one of the founding members of ISBER ... - in 1999, he served as its second president, ... In 2005, Dr. Vaught began working with the National ...
Breaking Biology Technology:Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3Omixon Launches Holotype HLA for NGS-based HLA Genotyping 2Omixon Launches Holotype HLA for NGS-based HLA Genotyping 3Dr. Jim Vaught, Ph.D., Former Chief of BBRB, Joins Provia Laboratories as Advisory Board Member 2Dr. Jim Vaught, Ph.D., Former Chief of BBRB, Joins Provia Laboratories as Advisory Board Member 3
... NEW HAVEN, Conn., Aug. 5 Rib-X Pharmaceuticals, Inc. ... discovery, development and commercialization of novel antibiotics for the treatment ... 2 clinical trial of radezolid in the treatment of community-acquired ... double-blind study, radezolid was administered orally at three different doses: ...
... , SANTA MONICA, Calif., Aug. 5 Cord ... stem cell preservation company ( http://www.cordblood-america.com ) ... families nationwide and internationally, said today it has retired $2.53M of ... in February and March of 2007 respectively, between CBAI and the ...
... ... medical exposition of its kind. John Rizvi will deliver a presentation titled, "Preservation of ... , ... 5, 2009 -- On August 13, 2009 at 1:00 PM, attorney John Rizvi will deliver ...
Cached Biology Technology:Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia 2Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia 3Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia 4Cord Blood America Retires $2.53M Obligation 2Cord Blood America Retires $2.53M Obligation 3Patent Attorney John Rizvi Speaks at FIME International Medical Expo 2
(Date:7/21/2014)... are reasons mammoths and mastodons could have been the ... from the University of Cincinnati, the famously fuzzy relatives ... it was trendy at the end of the ... an assistant professor of geology and anthropology, shows the ... were year-round residents and not nomadic migrants as previously ...
(Date:7/21/2014)... La. Dr. Mark DeCoster, the James E. ... Louisiana Tech University, will present as an invited ... at the Biopolis Research and Development Center in ... faculty member in Louisiana Tech,s Institute for Micromanufacturing, ... 2D and 3D cell and tissue models." ...
(Date:7/21/2014)... resistance, and cheating in science are among the ... and mycology experts in Montreal at the three ... July 27 to August 1, 2014. Some 2,000 ... at the 14th International Congress of Bacteriology and ... and Eukaryotic Microbiology, and the 16th International Congress ...
Breaking Biology News(10 mins):Mammoth and mastodon behavior was less roam, more stay at home 2Mammoth and mastodon behavior was less roam, more stay at home 3Louisiana Tech University professor presents at International Bioprinting Congress 2Montreal hosts International Union of Microbiology Societies congresses 2
... research professor and professor emeritus at The University of ... the American Academy of Arts & Sciences (AAAS), along ... Earl Jones, U.S. Secretary of Defense Robert Gates and ... scientist who translates his discoveries into technology that helps ...
... New York Sea Grant (NYSG) announces the release of ... Populations in South Shore Bays of Long Island, NY, ... of five research projects funded through NYSG,s Hard Clam ... NOAA National Marine Fisheries Service, South Shore Estuary Reserve, ...
... In Maine, government scientists have figured out how to measure ... and the sun - all the while saving money, energy, ... this energy-efficient ingenuity was the need to help the National ... spring snowmelt. The problem was this: While the USGS ...
Cached Biology News:University of Texas at Austin engineer elected to American Academy of Arts and Sciences 2University of Texas at Austin engineer elected to American Academy of Arts and Sciences 3Sea Grant report synthesizes recent research on New York's clams 2Measuring snow with a bucket, a windmill, and the sun? 2
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Request Info...
Biology Products: